-
Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in a Phase I clinical study for its STP705, targeting adult abdominal fat reduction. The study, expected to report results during the first half of 2023, marks a significant step forward in the development of non-invasive…
-
China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth
•
A total of 449 pharmaceutical and health-tech companies listed in China have released their H1 2022 financial reports, with over 40% reporting growth in both revenues and net profits. Among these, 14 companies recorded net profits exceeding RMB 2 billion (USD 287 million). Andon Health led the pack with RMB…
-
Suzhou InnoBM Pharmaceuticals Raises Series A+ Funding for Tumor Immunotherapy
•
China-based Suzhou InnoBM Pharmaceuticals reportedly raised tens of millions of renminbi in a Series A+ financing round led by Yuanbio Venture Capital. The proceeds will be used to advance clinical studies for tumor immunotherapies and develop pipeline candidates based on its unique biomaterial technology platform. Company BackgroundFounded in 2019, InnoBM…
-
Laekna Therapeutics Doses First Patient in LAE001/LAE002 Study for Prostate Cancer
•
China-based Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in the Phase I/II LAE201INT2101 study evaluating the combination of LAE001 and LAE002 (afuresertib) in South Korea. The multi-regional clinical trial (MRCT) now spans China, the United States, and South Korea. Study DetailsLAE201INT2101 is a multi-center,…
-
NHSA Reveals Drugs Passing Initial Review for NRDL Inclusion
•
The National Healthcare Security Administration (NHSA) released a notification listing the drugs that have passed the preliminary formal review for consideration in this year’s adjustment to the National Reimbursement Drug List (NRDL). The public feedback period is open from September 6 to 12. Review ResultsThe NHSA received a total of…
-
Innovent’s Tyvyt Combo Shows PFS Benefit in EGFR-Mutant NSCLC
•
China-based Innovent Biologics Inc. (HKG: 1801) announced positive results from the Phase III ORIENT-31 study evaluating the combination of its PD-1 inhibitor Tyvyt (sintilimab) and Byvasda (bevacizumab biosimilar) in patients with EGFR-mutated non-squamous non-small cell lung cancer (nsqNSCLC) who have progressed after EGFR tyrosine kinase inhibitor (TKI) treatment. The study…
-
Huadong Medicine Pays EUR 105M for 35% Stake in Heidelberg Pharma
•
China’s Huadong Medicine Co., Ltd (SHE: 000963) announced that it has paid a total of EUR 105 million (USD 105 million) to Germany-based Heidelberg Pharma AG (FSE: HPHA) in three installments, as per the agreement signed in February this year. Stake and Board RepresentationAs of the deal’s closure, Huadong holds…
-
CStone Pharmaceuticals Partners with Rigen Biotech on Thyroid Cancer RET Gene Testing
•
China-based CStone Pharmaceuticals (HKG: 2616) has entered into a partnership with Shanghai Rigen Biotech to collaborate on thyroid cancer RET gene testing business. Under the agreement, the two companies will jointly conduct thyroid cancer precision diagnosis and treatment academic activities, collaborate on thyroid cancer RET gene detection projects, and assist…
